In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
about
Ceftobiprole medocaril in the treatment of hospital-acquired pneumoniaCeftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Combination of alpha-melanocyte stimulating hormone with conventional antibiotics against methicillin resistant Staphylococcus aureus.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelRapid detection of Staphylococcus aureus strains with reduced susceptibility to vancomycin by isothermal microcalorimetry.
P2860
In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@ast
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@en
type
label
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@ast
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@en
prefLabel
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@ast
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@en
P2093
P2860
P356
P1476
In vivo synergism of ceftobipr ...... mediate Staphylococcus aureus.
@en
P2093
J M Entenza
J Vouillamoz
P Majcherczyk
P Moreillon
T R Veloso
P2860
P304
P356
10.1128/AAC.00402-11
P407
P577
2011-07-05T00:00:00Z